Sit At Our Glass Table
We’re On A Mission
Learn Our Latest
Sprout Pharmaceuticals, Inc. (Sprout) announced today that healthcare prescribers and pharmacies can now complete training to become certified to prescribe or dispense the medication through the Addyi Risk Evaluation and Mitigation Strategy (REMS) Program.
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
Sprout Pharmaceuticals, Inc. (Sprout) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of Addyi™ (flibanserin 100 mg) (pronounced add-ee), a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.